RU2012127261A - PHARMACEUTICAL COMPOSITION OF CHONDROPROTECTORS FOR TRANSDERMAL USE - Google Patents
PHARMACEUTICAL COMPOSITION OF CHONDROPROTECTORS FOR TRANSDERMAL USE Download PDFInfo
- Publication number
- RU2012127261A RU2012127261A RU2012127261/15A RU2012127261A RU2012127261A RU 2012127261 A RU2012127261 A RU 2012127261A RU 2012127261/15 A RU2012127261/15 A RU 2012127261/15A RU 2012127261 A RU2012127261 A RU 2012127261A RU 2012127261 A RU2012127261 A RU 2012127261A
- Authority
- RU
- Russia
- Prior art keywords
- emulsion according
- phospholipid emulsion
- phospholipid
- nanosomes
- salts
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
1. Фосфолипидная эмульсия, включающая липосомы (наносомы) со средним диаметром липосом (наносом) от 20 до 500 нм, содержащая этанол и воду, характеризующаяся тем, что дополнительно содержит лецитин с содержанием фосфатидилхолина не менее 60% и хондропротектор, который выбирают из группы: хондроитин и его соли и глюкозамин и его соли, при следующем соотношении компонентов липосом и активного вещества, мас.%:2. Фосфолипидная эмульсия по п.1, отличающаяся тем, что дополнительно содержит по меньшей мере, один биологически активный компонент и/или один фармакологически активный агент (фармацевтическую субстанцию)3. Фосфолипидная эмульсия по любому из пп.1 и 2, содержащая по крайней мере один приемлемый вспомогательный компонент в качестве разбавителя.4. Фосфолипидная эмульсия по п.1, отличающаяся тем, что эмульсия позволяет дозировать фармакологически активный компонент в эффективных количествах и ограничивать их верхний предел.5. Фосфолипидная эмульсия по п.1, отличающаяся тем, что содержит по крайней мере одно из вспомогательных веществ, выбираемых из групп консервантов, ароматической композиции.1. Phospholipid emulsion, including liposomes (nanosomes) with an average diameter of liposomes (nanosomes) from 20 to 500 nm, containing ethanol and water, characterized in that it additionally contains lecithin with a phosphatidylcholine content of at least 60% and a chondroprotector, which is selected from the group: chondroitin and its salts and glucosamine and its salts, in the following ratio of liposome components and active substance, wt.%: 2. The phospholipid emulsion according to claim 1, characterized in that it further comprises at least one biologically active component and / or one pharmacologically active agent (pharmaceutical substance) 3. The phospholipid emulsion according to any one of claims 1 and 2, containing at least one acceptable auxiliary component as a diluent. The phospholipid emulsion according to claim 1, characterized in that the emulsion allows you to dose the pharmacologically active component in effective quantities and limit their upper limit. The phospholipid emulsion according to claim 1, characterized in that it contains at least one of the excipients selected from the groups of preservatives, aromatic composition.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012127261/15A RU2012127261A (en) | 2012-07-02 | 2012-07-02 | PHARMACEUTICAL COMPOSITION OF CHONDROPROTECTORS FOR TRANSDERMAL USE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012127261/15A RU2012127261A (en) | 2012-07-02 | 2012-07-02 | PHARMACEUTICAL COMPOSITION OF CHONDROPROTECTORS FOR TRANSDERMAL USE |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012127261A true RU2012127261A (en) | 2014-01-20 |
Family
ID=49944600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012127261/15A RU2012127261A (en) | 2012-07-02 | 2012-07-02 | PHARMACEUTICAL COMPOSITION OF CHONDROPROTECTORS FOR TRANSDERMAL USE |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2012127261A (en) |
-
2012
- 2012-07-02 RU RU2012127261/15A patent/RU2012127261A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591662A1 (en) | LIPIDS AND LIPID COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | |
EA202191559A1 (en) | MODIFIED AMINE LIPIDS | |
EA201490489A1 (en) | PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7 | |
EA201490921A1 (en) | SUSTAINABLE COMPOSITIONS WITH CONTROLLED SHIPPING | |
EA201200939A1 (en) | LIPIDS, LIPID COMPOSITIONS AND METHODS OF THEIR APPLICATION | |
AR077338A1 (en) | PHARMACEUTICAL FORMULATION PREPARATION PROCEDURE DISSOLUTION FOR PERFUSION. | |
ECSP14012527A (en) | DPA-ENRICHED COMPOSITIONS OF POLYINSATURATED OMEGA 3 FATTY ACIDS IN FREE ACID FORM | |
PE20130216A1 (en) | TOPICAL FORMULATION FOR A JAK INHIBITOR | |
PE20160681A1 (en) | DEXMEDETOMIDINE PREMIX FORMULATION | |
RU2013141845A (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A CREAM CONTAINING OXYMETAZOLINE FOR THE TREATMENT OF ROSATSEA SYMPTOMS | |
BR112015007778A2 (en) | vegf neutralizing prodrugs for the treatment of eye conditions | |
UA109421C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING SIGMA-RECEPTOR LIGANDS | |
RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
EP3033089A2 (en) | Uses of phospholipid conjugates of synthetic tlr7 agonists | |
PE20110642A1 (en) | TOPIC ANTIFUNGAL FORMULATIONS BASED ON TERBINAFINE AND TERBINAFINE-SIMILAR COMPOUNDS AND METHODS OF USE | |
RU2009138047A (en) | VITAMIN B12 STABILIZATION | |
CO6351778A2 (en) | NAFTILACETIC ACIDS | |
AR070026A1 (en) | SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS | |
JP2013519653A5 (en) | ||
CO6852073A2 (en) | Trpm8 antagonists and their use in treatments | |
IN2014MN01571A (en) | ||
CO2022017622A2 (en) | nek7 kinase inhibitors | |
RU2006131812A (en) | PHARMACEUTICAL COMPOSITION OF ANTI-INFLAMMATORY AND ANTIMICROBIC ACTION IN THE FORM OF OILS ON A HYDROPHOBIC BASIS FOR TREATMENT OF SKIN DISEASES (OPTIONS) | |
JP2015506922A5 (en) | ||
EA201591653A1 (en) | COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS USING DIPYRIDAMOL |